BioSpace News Archive

As per a study by Fact.MR, the global anti-snoring treatment market is expected to surpass a valuation of US$ 8.6 billion by the year 2031.

5G is the fifth generation of cellular wireless technology, which can offer massive connection power and fast internet speed for data transfer.

Albireo Pharma, Inc., a clinical-stage rare liver disease company developing novel bile acid modulators, announced new data in nine accepted abstracts to be presented at EASL International Liver Congress™ 2021 on June 23 – 26.

Gilead Sciences, Inc. announced that more than 70 abstracts from the company’s liver disease programs will be presented at The International Liver Congress™ 2021 taking place from June 23-26.

Pharnext SA, an advanced late-stage clinical biopharmaceutical company pioneering new approaches to developing innovative drug combinations based on big genomics data and artificial intelligence using its PLEOTHERAPY platform, published a Letter to Shareholders from its Chief Executive Officer, Dr. David Horn Solomon.

Inogen, Inc., a medical technology company offering innovative respiratory products for use in the homecare setting, announced that its Board of Directors has appointed Jason Somer as Inogen’s Executive Vice President and General Counsel and Secretary, effective July 12, 2021.

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, announced multiple presentations at the 28th Annual FSHD Society International Research Congress.

Jafron Biomedical, a pioneer in the blood purification industry, announced it’s founding the Global Advisory Board, which includes the world’s top medical experts in clinical research and critical care medicine.

Castle Biosciences, Inc., a dermatologic diagnostics company providing personalized genomic information to inform treatment decisions, announced it has been included in the Houston Chronicle’s list of the 100 most successful publicly traded companies in the Houston area.

XOMA Corporation today announced its Board of Directors has authorized the following cash dividends to holders of XOMA’s Series A and Series B Cumulative Preferred Stock: